11月全新NCCN指南发布合集

2016-11-28 MedSci MedSci原创

近日,美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)又发布了一系列新指南,梅斯医学编辑对此进行汇总,与大家分享。1.2.3.4.5.6.7.8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675272, encodeId=f5a916e52726e, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Mon Jul 31 21:48:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159254, encodeId=f527159254fd, content=都17了,我去,16还没过, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef621732290, createdName=Tulipzyz, createdTime=Wed Nov 30 23:32:55 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319806, encodeId=f1e6131980689, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Nov 30 00:48:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159026, encodeId=a37c15902609, content=太强大了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3e1928208, createdName=顾小北大魔王, createdTime=Wed Nov 30 00:12:13 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675272, encodeId=f5a916e52726e, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Mon Jul 31 21:48:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159254, encodeId=f527159254fd, content=都17了,我去,16还没过, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef621732290, createdName=Tulipzyz, createdTime=Wed Nov 30 23:32:55 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319806, encodeId=f1e6131980689, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Nov 30 00:48:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159026, encodeId=a37c15902609, content=太强大了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3e1928208, createdName=顾小北大魔王, createdTime=Wed Nov 30 00:12:13 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2016-11-30 Tulipzyz

    都17了,我去,16还没过

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1675272, encodeId=f5a916e52726e, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Mon Jul 31 21:48:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159254, encodeId=f527159254fd, content=都17了,我去,16还没过, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef621732290, createdName=Tulipzyz, createdTime=Wed Nov 30 23:32:55 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319806, encodeId=f1e6131980689, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Nov 30 00:48:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159026, encodeId=a37c15902609, content=太强大了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3e1928208, createdName=顾小北大魔王, createdTime=Wed Nov 30 00:12:13 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675272, encodeId=f5a916e52726e, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Mon Jul 31 21:48:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159254, encodeId=f527159254fd, content=都17了,我去,16还没过, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef621732290, createdName=Tulipzyz, createdTime=Wed Nov 30 23:32:55 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319806, encodeId=f1e6131980689, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Nov 30 00:48:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159026, encodeId=a37c15902609, content=太强大了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3e1928208, createdName=顾小北大魔王, createdTime=Wed Nov 30 00:12:13 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2016-11-30 顾小北大魔王

    太强大了?

    0

相关资讯

2017.2版肺癌NCCN新鲜出炉啦!治疗格局大改变!

近日公布的2017版NCCN指南焕然一新,靶向及免疫治疗的飞速进展彻底改变了我们延习多年的NSCLC治疗模式。尤其是在晚期非小细胞肺癌的治疗流程及一线进展后临床处理上,展现出了很多新面孔。下面就以2016.4版及2017.2版的NCCN指南对比来详细解析。近日公布的2017版NCCN指南焕然一新,靶向及免疫治疗的飞速进展彻底改变了我们延习多年的NSCLC治疗模式。尤其是在晚期非小细胞肺癌的治疗流程

2016NCCN临床实践指南——戒烟(2016.V1)发布

2016年9月,美国国家综合癌症网络(NCCN)发布了戒烟指南2016年第1版,指南更新摘要如下:戒烟指南的一般原则,患者吸烟的初步评估,当前吸烟者及吸烟持续30天的人群,近前吸烟者和戒烟,癌症治疗期间一般戒烟方法,替代方法戒烟原则,癌症患者吸烟相关的风险,患者/供应者戒烟资源,戒烟与癌症手术,行为策略原则,戒烟药物治疗原则。全文获取:下载地址:指南下载 (需要扣积分2分, 梅

2012 NCCN年会:NCCN肿瘤指南更新要点汇总

       肺癌指南 更新多        今年非小细胞肺癌指南更新颇多,包括对电视胸腔镜手术(VATS)、新药Crizotinib的推荐以及修订腺癌分期等。        分期推荐:EUS/EBUS及原位腺癌       &nb

盘点:2017年全新NCCN指南汇总(上)

下接【盘点】2017年NCCN最新指南汇总(下) 1、2017 NCCN临床实践指南:宫颈癌(2017.V1)2016年10月,美国国家综合癌症网络(NCCN)发布了宫颈癌指南2017年第1版。(文章详见:2017 NCCN临床实践指南:宫颈癌(2017.V1))2、2017 NCCN临床实践指南:非小细胞肺癌(2017.V1)2016年10月,美国国家综合癌症网络(NCCN)发布了非小

ROS1基因检测首次写入NCCN指南

近日公布的2017版NCCN指南焕然一新,靶向及免疫治疗的飞速发展彻底改变了我们延习多年的NSCLC治疗模式。尤其是在晚期非小细胞肺癌的治疗流程及一线进展后临床处理上,展现出了很多新面孔。本篇文章主要介绍ROS1基因在非小细胞肺癌指南中的全新定位。靶向治疗及免疫治疗在近几年来取得了许多突破性的进展,推动了恶性肿瘤精准医疗的发展。在非小细胞肺癌(non-small cell lung cancer,

2016NCCN临床实践指南——中枢神经系统肿瘤(2016.V1)发布

2016年7月,美国国家综合癌症网络(NCCN)发布了中枢神经系统肿瘤指南2016年第1版,指南更新摘要如下:指南更新摘要 成人低渗透性的幕上星形细胞瘤/少突神经胶质瘤(不含Pilocytic星形细胞瘤) 间变性胶质瘤/恶性胶质瘤 成人颅内和脊髓室管膜瘤(不含亚室管膜瘤)  成人成神经管细胞瘤和幕上的PNET 原发性中枢神经系统淋巴瘤